0001144204-18-020537.txt : 20180413 0001144204-18-020537.hdr.sgml : 20180413 20180413170039 ACCESSION NUMBER: 0001144204-18-020537 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180315 ITEM INFORMATION: Unregistered Sales of Equity Securities FILED AS OF DATE: 20180413 DATE AS OF CHANGE: 20180413 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001187953 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 870622284 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-53500 FILM NUMBER: 18754897 BUSINESS ADDRESS: STREET 1: 2017 W PEORIA AVENUE CITY: PHOENIX STATE: AZ ZIP: 85029 BUSINESS PHONE: (602) 680-7439 MAIL ADDRESS: STREET 1: 2017 W PEORIA AVENUE CITY: PHOENIX STATE: AZ ZIP: 85029 FORMER COMPANY: FORMER CONFORMED NAME: JOLLEY MARKETING INC DATE OF NAME CHANGE: 20020910 8-K 1 tv491060_8k.htm FORM 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 15, 2018

 

Creative Medical Technology Holdings, Inc.

(Exact name of registrant as specified in its charter)

 

Nevada   000-53500   87-0622284

(State or other jurisdiction of

incorporation)

   (Commission File Number)  

(I.R.S. Employer

Identification No.)

 

2017 W Peoria Avenue, Phoenix, AZ 85029
(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (602) 680-7439

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

 

Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 3.02Unregistered Sales of Equity Securities.

 

From March 2, 2018 through April 12, 2018, we issued an aggregate of 144,585,823 shares upon the conversions of outstanding notes and 92,023,304 shares upon the cashless exercise of outstanding warrants. These conversions were made pursuant to the exemption provided by Section 3(a)(9) of the Securities Act of 1933. As a result of these issuances, we have outstanding 480,035,712 shares of common stock as of April 12, 2018.

  

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Creative Medical Technology Holdings, Inc.
   
   
Date: April 12, 2018 By: /s/ Timothy Warbington
    Timothy Warbington, Chief Executive Officer